Company Overview

Novo Nordisk A/S is a global pharmaceutical company headquartered in Denmark that specializes in the discovery, development, manufacturing, and commercialization of medicines for chronic diseases. The company primarily operates within the diabetes care, obesity treatment, and rare disease industries, with a strong emphasis on biologic therapies. Its core revenue drivers are injectable and oral treatments for diabetes and obesity, alongside products for hemophilia and other rare endocrine and metabolic disorders.

The company’s strategic positioning is built on deep expertise in insulin and peptide-based therapies, large-scale biologics manufacturing, and sustained investment in research and development. Novo Nordisk has evolved from a regional insulin producer founded in 1923 into one of the world’s largest pharmaceutical companies by market capitalization, driven by scientific innovation, long-term disease focus, and strong execution in global healthcare markets.

Business Operations

Novo Nordisk operates through several core business segments, primarily Diabetes and Obesity Care and Rare Disease, which together generate the majority of company revenue. The diabetes and obesity segment includes insulin products, GLP‑1 receptor agonists, and combination therapies, while the rare disease segment focuses on treatments for hemophilia, growth hormone disorders, and other endocrine conditions. Revenue is generated through the sale of branded prescription medicines to healthcare systems, hospitals, and pharmacies.

The company maintains fully integrated operations, controlling research, clinical development, manufacturing, and global distribution. It operates advanced biologics production facilities and maintains long-term partnerships with healthcare providers and distributors. Novo Nordisk also has wholly owned subsidiaries responsible for regional sales and manufacturing, including Novo Nordisk Inc. in the United States, which represents its largest single-market operation.

Strategic Position & Investments

Novo Nordisk’s strategic direction centers on expanding leadership in obesity and cardiometabolic diseases while sustaining its dominant position in diabetes care. Growth initiatives include scaling production capacity for GLP‑1–based therapies, expanding indications for existing products, and advancing late-stage clinical pipelines in obesity, cardiovascular risk reduction, and metabolic disorders.

The company has made targeted acquisitions and strategic investments to strengthen its technology base and manufacturing footprint, including acquisitions of specialized biotech and production assets to support peptide and biologics manufacturing. Novo Nordisk also invests through its controlling shareholder structure in long-term innovation and emerging therapeutic platforms, with a focus on metabolic science and chronic disease management.

Geographic Footprint

Novo Nordisk operates in more than 80 countries and markets its products in most major global healthcare markets. Its corporate headquarters and primary research facilities are located in Denmark, while the United States represents its largest commercial market. Significant operational hubs also exist across Europe, Asia-Pacific, China, and Latin America, supporting both sales and manufacturing activities.

Manufacturing facilities are strategically located across Denmark, the United States, France, China, and Brazil, enabling regional supply resilience and regulatory compliance. The company’s global footprint supports broad international access to its therapies and positions it as a key supplier to both developed and emerging healthcare systems.

Leadership & Governance

Novo Nordisk operates under a two-tier governance structure with a strong emphasis on long-term value creation, scientific integrity, and sustainability. The company is controlled by the Novo Nordisk Foundation through majority voting power, which influences its long-term strategic orientation. Leadership emphasizes patient-centric innovation, ethical business practices, and responsible growth.

Key executives include:

• Lars Fruergaard Jørgensen – President and Chief Executive Officer
• Karsten Munk Knudsen – Executive Vice President and Chief Financial Officer
• Martin Holst Lange – Executive Vice President, Development
• Marcus Schindler – Executive Vice President, Research and Early Development
• Dave Moore – Executive Vice President, U.S. Operations

The executive team collectively drives strategy across research, commercialization, and global operations, aligning scientific development with long-term shareholder and societal objectives.